1015 Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-7
Closed -$3.48K – 565
2026
Q2
$3.48K Hold
7
– – ﹤0.01% 274
2026
Q1
$3.13K Buy
7
+1
+17% +$466 ﹤0.01% 274
2025
Q4
$2.72K Hold
6
– – ﹤0.01% 284

Other funds holding VRTX

1015 Capital Partners's VRTX Position: Q3 2026 in Review

1015 Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2026, closing a stake of 7 shares — an estimated $3.48K sold.

1015 Capital Partners first reported a position in VRTX in Q4 2025 and held it in 3 quarters. The position peaked at $3.48K in Q2 2026. 1,796 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • 1015 Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • 1015 Capital Partners sold 7 Vertex Pharmaceuticals shares in Q3 2026, an estimated $3.48K.
  • 1015 Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • 1015 Capital Partners's Vertex Pharmaceuticals position peaked at $3.48K in Q2 2026.
  • 1,796 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on 1015 Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.